The National Institutes of Health (NIH) intends to award a non-competitive contract to Invivoscribe, Inc. for a Clinical Laboratory Molecular Diagnostics Test using their reagent kit. This test is used to identify clonal immunoglobulin gene rearrangements for diagnosing B-cell malignancies and monitoring disease recurrence in cancer patients. The contract will be conducted under simplified acquisition procedures, with an amount not exceeding the simplified acquisition threshold of $350,000. The performance location is at the NIH in Bethesda, Maryland. Interested parties must submit their responses by June 29, 2026, at 9:00 AM Eastern time.